Windtree Therapeutics (NASDAQ: WINT) announced an agreement with affiliates of biopharma investor Deerfield Management Company to fully retire a $15 million contingent liability associated with Windtree’s Aerosurf®, a drug and device combination treatment for premature infants with respiratory dis

Related Keywords

, Windtree Aerosurf , Craig Fraser , Windtree Therapeutics , Lee Pharmaceuticals , Deerfield Management Company , Chief Executive , Targeting Phase , Wance Paleri ,